welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).

expertly curated content related to this topic
-
Prevalence of Small Bowel Polyps in Patients With Sporadic Duodenal AdenomasLittle is known about the prevalence of ...
-
Don J. Schiller, MD, Celebrates 25 Years of Surgical SafetyDon J. Schiller, MD, Celebrates 25 Years...
-
polyposis (polypeople)FAP is an inherited condition which main...
-
Hisham Hussan, MDSpecialties/Interests: Gastroenterology,...
-
Bon Voyage: Traveling with a J-Pouch Part 1https://www.youtube.com/watch?v=NlhsEEuo...
-
@FAPStudyDo you suffer from F.A.P.? There's a cli...
-
Global Quantitative Assessment of the Colorectal Polyp Burden in Familial Adenomatous Polyposis by Using a Web-based...BACKGROUND: Accurate measures of the to...